نمایش پرونده ساده آیتم

dc.contributor.authorEbrahimi, AA
dc.contributor.authorNoshad, H
dc.contributor.authorSadreddini, S
dc.contributor.authorHejazi, MS
dc.contributor.authorSadigh, YM
dc.contributor.authorEshraghi, Y
dc.contributor.authorGhojazadeh, M
dc.date.accessioned2018-08-26T09:34:42Z
dc.date.available2018-08-26T09:34:42Z
dc.date.issued2009
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/57776
dc.description.abstractBackground: Rheumatoid arthritis (RA) is a chronic multisystem autoimmune disease common in all races and ethnics. Cytokines and cytokines receptors play an important role in RA pathogenesis and clinical presentation. Objective: To investigate the serum levels of TNF-?, TNF-? RI, TNF-? RII and IL-12 in RA patients and healthy control group. Methods: In this study 43 patients fulfilling the revised criteria of American College of Rheumatology (ACR) for RA and 13 healthy cases as a control group were selected for TNF-?, TNF-?RI, TNF-?RII and IL-12 serum level analysis. The patients' age was 42.2 ± 22 and the age of healthy group was 40.1 ± 19.2 years (p=0.1). The pa-tients had an active disease with at least six swollen and ten tender joints. Minimum ESR was 28 mm at first hours of the morning. Early morning stiffness in patients lasted longer than 45 minutes. Results: Our study showed that IL-12 serum level of the pa-tients (91.69 ± 43.07 ?g/ml) and control (61.79 ± 40.08 ?g/ml) group was significantly different (p<0.001). The serum level of TNF-?RI was 2.36 ± 0.77 ng/ml in the patient and 1.73 ± 0.37 ng/ml in the control group (p<0.01). TNF-?RII serum concentration in patients was 8.89 ± 2.3 ng/ml, while that of control group was 7.06±1.30 ng/ml (p=0.03). The serum level of TNF-? in patients was 32.90 ± 19.27 ?g/ml and that of the control group was 24.27± 8.28 ?g/ml (p=0.08) with no significant difference between the two. Conclusions: It is concluded that IL-12, TNF-?RI and TNF- ?RII serum con-centrations are more important and better predictive factors than TNF-? in RA course and in the active forms of the disease.
dc.language.isoEnglish
dc.relation.ispartofIranian Journal of Immunology
dc.subjectantiinflammatory agent
dc.subjectC reactive protein
dc.subjectdisease modifying antirheumatic drug
dc.subjecthydroxychloroquine
dc.subjectinterleukin 2
dc.subjectmethotrexate
dc.subjectnonsteroid antiinflammatory agent
dc.subjectsalazosulfapyridine
dc.subjectsteroid
dc.subjecttumor necrosis factor alpha
dc.subjecttumor necrosis factor alpha receptor
dc.subjecttumor necrosis factor alpha receptor 1
dc.subjecttumor necrosis factor alpha receptor 2
dc.subjectunclassified drug
dc.subjectinterleukin 12
dc.subjecttumor necrosis factor alpha
dc.subjecttumor necrosis factor receptor 1
dc.subjecttumor necrosis factor receptor 2
dc.subjectadult
dc.subjectarticle
dc.subjectclinical article
dc.subjectclinical evaluation
dc.subjectcontrolled study
dc.subjectdisease course
dc.subjectdisease duration
dc.subjecterythrocyte sedimentation rate
dc.subjectfemale
dc.subjecthuman
dc.subjectjoint swelling
dc.subjectmale
dc.subjectmorning stiffness
dc.subjectpredictive value
dc.subjectprotein blood level
dc.subjectprotein function
dc.subjectrheumatoid arthritis
dc.subjectblood
dc.subjectmiddle aged
dc.subjectrheumatoid arthritis
dc.subjectAdult
dc.subjectArthritis, Rheumatoid
dc.subjectFemale
dc.subjectHumans
dc.subjectInterleukin-12
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectReceptors, Tumor Necrosis Factor, Type I
dc.subjectReceptors, Tumor Necrosis Factor, Type II
dc.subjectTumor Necrosis Factor-alpha
dc.titleSerum Levels of TNF-?, TNF-?RI, TNF-?RII and IL-12 in Treated Rheumatoid Arthritis Patients
dc.typeArticle
dc.citation.volume6
dc.citation.issue3
dc.citation.spage147
dc.citation.epage153
dc.citation.indexScopus


فایلهای درون آیتم

Thumbnail

این آیتم در مجموعه های زیر مشاهده می شود

نمایش پرونده ساده آیتم